Ignite Creation Date:
2025-12-24 @ 10:13 PM
Ignite Modification Date:
2026-02-25 @ 5:22 PM
Study NCT ID:
NCT03824535
Status:
COMPLETED
Last Update Posted:
2025-04-09
First Post:
2019-01-29
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2024-11-22', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D016540', 'term': 'Smoking Cessation'}, {'id': 'D055613', 'term': 'Multiple Pulmonary Nodules'}], 'ancestors': [{'id': 'D015438', 'term': 'Health Behavior'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D014057', 'term': 'Tomography, X-Ray Computed'}, {'id': 'D014054', 'term': 'Tomography'}, {'id': 'D019788', 'term': 'Fluorodeoxyglucose F18'}, {'id': 'C000623325', 'term': '4-(3-fluoropropyl)glutamic acid'}, {'id': 'D049268', 'term': 'Positron-Emission Tomography'}, {'id': 'D000072078', 'term': 'Positron Emission Tomography Computed Tomography'}, {'id': 'D003952', 'term': 'Diagnostic Imaging'}], 'ancestors': [{'id': 'D007090', 'term': 'Image Interpretation, Computer-Assisted'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D011856', 'term': 'Radiographic Image Enhancement'}, {'id': 'D007089', 'term': 'Image Enhancement'}, {'id': 'D010781', 'term': 'Photography'}, {'id': 'D011859', 'term': 'Radiography'}, {'id': 'D014056', 'term': 'Tomography, X-Ray'}, {'id': 'D003847', 'term': 'Deoxyglucose'}, {'id': 'D003837', 'term': 'Deoxy Sugars'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D014055', 'term': 'Tomography, Emission-Computed'}, {'id': 'D011877', 'term': 'Radionuclide Imaging'}, {'id': 'D003947', 'term': 'Diagnostic Techniques, Radioisotope'}, {'id': 'D064847', 'term': 'Multimodal Imaging'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'drmari@stanford.edu', 'phone': '650-497 9280', 'title': 'Dr. Carina Mari Aparici', 'organization': 'Stanford University'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Within 24 to 72hours after the 18F-FSPG PET/CT', 'eventGroups': [{'id': 'EG000', 'title': 'Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 0, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}, {'units': 'Nodules', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Diagnostic (18F-FSPG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}, {'id': 'OG001', 'title': 'Diagnostic (18F-FDG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}], 'classes': [{'title': 'Sensitivity', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000', 'lowerLimit': '100', 'upperLimit': '100'}, {'value': '70', 'groupId': 'OG001', 'lowerLimit': '35', 'upperLimit': '93'}]}]}, {'title': 'Specificity', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000', 'lowerLimit': '40', 'upperLimit': '100'}, {'value': '100', 'groupId': 'OG001', 'lowerLimit': '40', 'upperLimit': '100'}]}]}, {'title': 'Positive Predictive Value (PPV)', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000', 'lowerLimit': '100', 'upperLimit': '100'}, {'value': '100', 'groupId': 'OG001', 'lowerLimit': '100', 'upperLimit': '100'}]}]}, {'title': 'Negative Predictive Value (NPV)', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000', 'lowerLimit': '100', 'upperLimit': '100'}, {'value': '57', 'groupId': 'OG001', 'lowerLimit': '34', 'upperLimit': '77'}]}]}, {'title': 'Accuracy', 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000', 'lowerLimit': '77', 'upperLimit': '100'}, {'value': '79', 'groupId': 'OG001', 'lowerLimit': '49', 'upperLimit': '95'}]}]}], 'analyses': [{'pValue': '0.02', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'The threshold for statistical significance was set at p \\< 0.05', 'groupDescription': "Analysis applies to the row 'Specificity' in the Outcome Measure data table.", 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Through study completion, an average of 2 years and 6 months', 'description': 'The diagnostic performance of ultrasonography and capnography in detecting malignant lung nodules was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Sensitivity and specificity were calculated to determine the ability to correctly identify malignant and non-malignant nodules, respectively. Results were compared to a predefined threshold of 75%, with all percentages reported as proportions of the total number of nodules analyzed. Confidence intervals were calculated for each metric to ensure precision and reliability in the estimates.', 'unitOfMeasure': 'percentage', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'typeUnitsAnalyzed': 'Nodules', 'denomUnitsSelected': 'Nodules', 'populationDescription': 'One lesion per participant was evaluated; therefore, lesion and participant counts match 1:1.'}, {'type': 'SECONDARY', 'title': 'Improvement in Predictive Accuracy of Lung Nodule Diagnosis Using the C Statistic (Area Under the Curve, AUC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}, {'units': 'Nodules', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Baseline Diagnostic (18F-FSPG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}, {'id': 'OG001', 'title': 'Improved Diagnostic (18F-FDG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}], 'classes': [{'categories': [{'measurements': [{'value': '0.84', 'spread': '0.1', 'groupId': 'OG000'}, {'value': '1.0', 'spread': '0.0', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.004', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'The threshold for statistical significance was predefined as p \\< 0.05', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.05', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'The threshold for statistical significance was predefined as p ≤ 0.05.', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.06', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'The threshold for statistical significance was predefined as p \\< 0.05.', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Through study completion, an average of 2 years and 6 months', 'description': 'The predictive accuracy of the lung nodule diagnosis model was assessed using the C statistic, also referred to as the area under the receiver operating characteristic (ROC) curve (AUC). Improved performance was defined as a statistically significant increase (p \\< 0.05) in the C statistic, determined using the DeLong test for comparing correlated ROC curves. The Mann-Whitney U test was also used to compare the distributions of the C statistic between diagnostic methods. Results are reported as the mean C statistic with 95% confidence intervals for each diagnostic method.', 'unitOfMeasure': 'probability', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'typeUnitsAnalyzed': 'Nodules', 'denomUnitsSelected': 'Nodules'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)', 'description': 'Patients received 18F-FSPG IV and, underwent a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients received 18F-FDG IV and underwent a second PET/CT scan over 30-60 minutes.\n\nComputed Tomography: Undergo PET/CT\n\nFludeoxyglucose F-18: Given IV\n\nFluorine F 18 L-glutamate Derivative BAY94-9392: Given IV\n\nPositron Emission Tomography: Undergo PET/CT'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '13', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '5', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '10', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '11', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-06-08', 'size': 888657, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-10-24T11:25', 'hasProtocol': True}, {'date': '2023-10-24', 'size': 436538, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_002.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2024-10-18T13:26', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 15}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-02-04', 'type': 'ACTUAL'}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2021-07-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-07', 'studyFirstSubmitDate': '2019-01-29', 'resultsFirstSubmitDate': '2024-10-25', 'studyFirstSubmitQcDate': '2019-01-29', 'lastUpdatePostDateStruct': {'date': '2025-04-09', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-04-07', 'studyFirstPostDateStruct': {'date': '2019-01-31', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-04-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-07-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules', 'timeFrame': 'Through study completion, an average of 2 years and 6 months', 'description': 'The diagnostic performance of ultrasonography and capnography in detecting malignant lung nodules was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Sensitivity and specificity were calculated to determine the ability to correctly identify malignant and non-malignant nodules, respectively. Results were compared to a predefined threshold of 75%, with all percentages reported as proportions of the total number of nodules analyzed. Confidence intervals were calculated for each metric to ensure precision and reliability in the estimates.'}], 'secondaryOutcomes': [{'measure': 'Improvement in Predictive Accuracy of Lung Nodule Diagnosis Using the C Statistic (Area Under the Curve, AUC)', 'timeFrame': 'Through study completion, an average of 2 years and 6 months', 'description': 'The predictive accuracy of the lung nodule diagnosis model was assessed using the C statistic, also referred to as the area under the receiver operating characteristic (ROC) curve (AUC). Improved performance was defined as a statistically significant increase (p \\< 0.05) in the C statistic, determined using the DeLong test for comparing correlated ROC curves. The Mann-Whitney U test was also used to compare the distributions of the C statistic between diagnostic methods. Results are reported as the mean C statistic with 95% confidence intervals for each diagnostic method.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Indeterminate lung nodule'], 'conditions': ['Cigarette Smoker', 'Current Smoker', 'Former Smoker', 'Multiple Pulmonary Nodules', 'Pulmonary Nodule']}, 'descriptionModule': {'briefSummary': 'This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.', 'detailedDescription': 'PRIMARY OBJECTIVES:\n\nI. Comparison of fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) accumulation with fludeoxyglucose F-18 (18F-FDG) accumulation to assess whether (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate (18F-FSPG)-PET is better at discriminating between benign and malignant nodules.\n\nSECONDARY OBJECTIVES:\n\nI. To develop and validate early lung cancer detection biomarkers that would directly impact the growing need to integrate imaging and non-invasive molecular diagnostics for indeterminate pulmonary nodules and allow physicians to avoid unnecessary invasive procedures in patients with benign lung disease.\n\nOUTLINE:\n\nPatients receive 18F-FSPG intravenously (IV) and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG and undergo a second PET/CT scan over 30-60 minutes.\n\nAfter completion of study, patients are followed up within 24-72 hours.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '45 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm\n* Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)\n* Current or former cigarette smoker, with \\>= 20 pack years\n* Documented informed consent\n\nExclusion Criteria:\n\n* History or previous diagnosis of lung cancer\n* Cancer diagnosis within the last 5 years\n* Pregnant or nursing'}, 'identificationModule': {'nctId': 'NCT03824535', 'briefTitle': '18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules', 'organization': {'class': 'OTHER', 'fullName': 'Stanford University'}, 'officialTitle': '18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules', 'orgStudyIdInfo': {'id': 'IRB-46607'}, 'secondaryIdInfos': [{'id': 'NCI-2019-00177', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': 'LUN0106', 'type': 'OTHER', 'domain': 'Stanford Cancer Institute Palo Alto'}, {'id': 'IRB-46607', 'type': 'OTHER', 'domain': 'Stanford IRB'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)', 'description': 'Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.', 'interventionNames': ['Diagnostic Test: Computed Tomography', 'Drug: Fludeoxyglucose F-18', 'Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392', 'Diagnostic Test: Positron Emission Tomography (PET/CT)']}], 'interventions': [{'name': 'Computed Tomography', 'type': 'DIAGNOSTIC_TEST', 'otherNames': ['CAT', 'CAT Scan', 'Computerized Axial Tomography', 'computerized tomography', 'CT', 'CT SCAN', 'tomography'], 'description': 'Undergo PET/CT', 'armGroupLabels': ['Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)']}, {'name': 'Fludeoxyglucose F-18', 'type': 'DRUG', 'otherNames': ['18-FDG', 'FDG', 'fludeoxyglucose F 18', 'Fludeoxyglucose F18', 'Fluorine-18 2-Fluoro-2-deoxy-D-Glucose', 'Fluorodeoxyglucose F18'], 'description': 'Given IV', 'armGroupLabels': ['Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)']}, {'name': 'Fluorine F 18 L-glutamate Derivative BAY94-9392', 'type': 'DRUG', 'otherNames': ['(S)-4-(3-18F-fluoropropyl)-L-glutamic Acid', '18F-FSPG', 'BAY94-9392'], 'description': 'Given IV', 'armGroupLabels': ['Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)']}, {'name': 'Positron Emission Tomography (PET/CT)', 'type': 'DIAGNOSTIC_TEST', 'otherNames': ['Positron Emission Tomography/computer tomography', 'CT Scan', 'PET Scan', 'Positron Emission Tomography', 'medical imaging'], 'description': 'Undergo PET/CT', 'armGroupLabels': ['Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '94304', 'city': 'Palo Alto', 'state': 'California', 'country': 'United States', 'facility': 'Stanford Cancer Institute Palo Alto', 'geoPoint': {'lat': 37.44188, 'lon': -122.14302}}], 'overallOfficials': [{'name': 'Carina Mari Aparici', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Stanford Cancer Institute Palo Alto'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Andrei Iagaru', 'class': 'OTHER'}, 'collaborators': [{'name': 'Canary Foundation', 'class': 'OTHER'}, {'name': 'Boston University', 'class': 'OTHER'}, {'name': 'United States Department of Defense', 'class': 'FED'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Associate Professor of Radiology (Nuclear Medicine)', 'investigatorFullName': 'Andrei Iagaru', 'investigatorAffiliation': 'Stanford University'}}}}